Fig. 3From: Safety and efficacy of T-cell-redirecting bispecific antibodies for patients with multiple myeloma: a systematic review and meta-analysisGrade ≥3 hematologic and non-hematologic adverse events following administration of bispecific antibodies for patients with multiple myelomaBack to article page